Inovio Pharmaceuticals, Inc. - Common Stock (INO)

Inovio's VOCERYQ launch plans and cash runway outlook are now in focus.

Inovio Pharmaceuticals (NASDAQ:INO) is preparing to launch its first approved product, VOCERYQ, after the Food and Drug Administration granted accelerated approval for the treatment of adults with recurrent respiratory papillomatosis, or RRP, the company said on its third-quarter earnings call. Chi

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP. VOCERYQ is the co

Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30. President and CEO Jacqueline Shea

Inovio Pharmaceuticals (NASDAQ:INO) is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat. Shea described Inovio as a clinical-stage company d

INO-3107 advances toward October FDA decision as company extends cash runway through early 2027.

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31,

Inovio (INO) Q1 2026 Earnings Call Transcript

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares are tumbling Thursday after the company announced the pricing of a proposed public offering.